EU countries unprepared to move future Alzheimer's treatment into rapid clinical use

(RAND Corporation) The burden of Alzheimer's disease in high-income countries is expected to nearly double by 2050 and recent positive results from clinical trials give hope that a disease-changing treatment could become available for routine use within a few years. But a new study finds that the health care systems in some European countries lack the capacity to rapidly move a disease-modifying treatment for Alzheimer's disease from approval into widespread clinical use.